Blockade of the HER3 receptor and of the downstream PI3K/AKT pathway is a prerequisite for overcoming drug-resistance and to develop novel treatments for cancers that are not eligible for the currently approved targeted therapies. To this end, we generated specific antibodies against domain 1 (D1) and domain 3 ( 
Introduction
trastuzumab after prolonged treatment, are "re-programmed" to strongly express HER3 [15] Cetuximab resistance is also associated with HER3 over-expression in lung [16] , colorectal [17] and pancreatic [18] cancers, together with deregulation of EGFR internalization/degradation [16, 18] .
Overexpression of HER3 and activation of the PI3K/AKT pathway are also implicated in the development of resistance to treatment with tyrosine kinase [19, 20] and PI3K [21] inhibitors, IGF1R-specific Abs [22] , chemotherapeutic agents and endocrine therapies.
Therefore HER3 could be involved in the efficacy reduction of many approved cancer monotherapies over time by (i) leading to oversensitivity to HER3 ligands, such as NRGs [17] , (ii) switching heterodimerization partner within the HER family or with other kinase receptors [16, 19] and (iii) compensatory up-regulation of signaling pathways [23] . Indeed, the current view is that EGFR-, HER2-or PI3K/AKT-targeted therapies (and probably other kinase receptor-triggered pathways) will not be effective in the long term unless combined with HER3 antagonists [21] . Most HER3-specific Abs described to date act by blocking the NRG binding site [13, [24] [25] [26] [27] [28] [29] . However, as HER3 plays a key role in both ligand-independent and -dependent oncogenic signaling [5] via paracrine or autocrine loops [30] , we postulated that anti-HER3 Abs that are not restricted to the ligand-binding site might have a wider scope of action and could be associated with antibodies that target the NRG binding site for a wider spectrum of action. The therapeutic efficacy of the anti-EGFR Ab matuzumab [31] , which does not target the EGF-binding site, indicates that Abs that are not directed against ligand-binding sites can have very interesting therapeutic perspectives in oncology. We thus generated antibodies that bind to motifs located on domain 1 (D1), 3 (D3) and 4 (D4) of HER3 and that, for some of them, do not overlap with the NRG binding site. These Abs reduced tumor growth in mice xenografted with different cancer cell lines, independently of their NRG addiction or triple-negative status. These Abs reduced HER2/HER3 heterodimerization at the cell membrane of tumor cells and inhibited AKTinduced phosphorylation of MDM2, FoxO1, XIAP, S6 and GSK-3, leading to reduced survival of tumor cells.
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Materials and Methods
Reagents
Trastuzumab was obtained from Roche Pharma AG (Grenzach-Wyhlen, Germany). The anti-HER2 Ab is an IgG 1 monoclonal Ab that was purified from the mouse myeloma cell line MOPC21. Recombinant human HER3 was acquired from Sino Biologicals (Beijing, China).
Cell lines
The human pancreatic (BxPC-3), breast (MDA-MB-468), epidermoid (A431) and lung (A549) cancer cell lines were from ATCC (Rockville, MD). The mouse embryonic fibroblast NIH/3T3 cell line was kindly provided by S. Schmidt (CNRS-UMR 5237, Montpellier, France). EGFR-, HER2-, HER3-, HER2/HER3-and EGFR/HER4-transfected NIH/3T3 cell lines were obtained as previously described [32] . Cell culture was detailed in the supplementary material.
Antibody generation
Anti-HER3 human antibody fragments were selected from the human scFv phage library MG-Umab 
HER3 binding studies
The binding specificity of selected Abs to soluble and membrane HER3 was assessed by ELISA, flow cytometry and surface plasmon resonance, and detailed in the supplementary material.
Epitope determination by SPOT peptide analysis
Two hundred and thirteen overlapping pentadecapeptides that were frame-shifted by one or three residues and that covered the amino acid sequence of the HER3 extracellular domain (amino acids 1 to 645), were synthesized on cellulose membrane. After 3 washes in TBS buffer (50 mM Tris, 137 mM NaCl, 2.68 mM KCl), membranes were saturated in TBS containing 5% sucrose and casein-based blocking buffer (TBS-sucrose-BB; 1:50; Sigma-Aldrich) at 25°C overnight. After three washes in TBS containing 0.05% Tween 20 (TBS-T), cellulose-bound peptides were probed with 1 to 10 g/ml anti-HER3 Abs in TBS-sucrose-BB and concomitantly or sequentially incubated with peroxidase- epitopes recognized by the selected Abs, were identified on the basis of the Ab-binding capacity of the relevant alanine analog (at least 20% lower than that of the unmodified peptide sequence).
Flow cytometry-based NRG-binding competition experiments
Competition experiments were performed in order to quantify the ability of NRG to inhibit Ab binding to HER3 in a SKBR3 cell-based assay. To this end, 10 5 SKBR3 cells were pre-incubated with various concentrations of the competing NRG ligand on ice for 1.5h. After one wash with PBS-1%
BSA, anti-HER3 Abs were added to each well at the concentration that gives 50% of the maximal binding, on ice for 1h. In some experiments, NRG ligand and anti-HER3 Abs were co-incubated on ice for 2h, and showed similar results. Cells were then washed and incubated with the appropriate FITCconjugated secondary Ab (1:60 dilution; Sigma) on ice for 45 min, before cytometric analysis on a Quanta apparatus (Beckman-Coulter).
Cell cycle, proliferation and apoptosis assays
The effect of HER3-specific Abs on the cell cycle was evaluated using propidium iodide staining.
Briefly, 300,000 BxPC3 tumor cells/well were cultured in 6-well microtiter plates for 24h, and then serum starved and synchronized in RPMI medium without FCS for another 24h, before co-incubation with 100 µg/ml anti-HER3 Abs and 100 ng/ml NRG. Permeabilized cells were stained 24h later with inserm-00815985, version 1 -19 Apr 2013
propidium iodide before flow cytometric analysis. For proliferation and apoptosis assays, 50,000
BxPC3 cells/well were plated one day before starvation (in RPMI-1% FCS). HER3-specific Abs and NRG were then added for 120h. Cell proliferation was measured by incorporating Alexa Fluor 488-conjugated 5-ethynyl-2'-deoxyuridine (EdU) (Invitrogen) during the last 30h of culture. Cell apoptosis was assessed by incubation with fluorescence-conjugated Annexin V and 7-aminoactinomycin D (7-AAD; Beckman-Coulter). All experiments were performed in triplicate.
Western blotting
Cellular fractionation of treated BxPC3 tumor cells and further western blot using appropriate antibodies were detailed in the supplementary material.
HTRF analysis of HER2/HER3 heterodimerization
HER2/HER3 heterodimers were quantified using antibody-based time-resolved fluorescence resonance energy transfer (TR-FRET) assay, as previously described [32] and detailed in the supplementary material.
Statistical analysis
A linear mixed regression model was used to determine the relationship between tumor growth and the number of days post-graft. The fixed part of the model included variables corresponding to the number of days post-graft and the different groups. Interaction terms were built into the model.
Random intercept and random slope were included to take into account the time effect. The coefficients of the model were estimated by maximum likelihood and considered significant at the 0.05 level. Survival rates were estimated from the date of the xenograft until the date when the tumor reached a volume of 2000 mm 3 using the Kaplan-Meier method. Median survival was presented with 95% confidence intervals. Survival curves were compared using the log-rank test.
Statistical analyses were carried out using the STATA 11.0 software (Stata Corp., College Station, TX).
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Results
Selected anti-HER3 antibodies bind to the extracellular region of human HER3, but not to the other HER receptors
Of the approximately 1000 mouse hybridomas screened, ten mouse Abs ( These two binding motifs are opposite to the H4B-121 epitope. The H4B-25 binding motif, which is involved in a -helix structure, was within a "hot-spot" region and overlapped with the HER3 epitope recognized by the "two-in-one" EGFR/HER3 antibody MEHD7945A [27] . Moreover, it included aminoacid positions that align with residues that are critically involved in the binding of MEHD7945A [27] , matuzumab [31] , nimotuzumab [34] and cetuximab [35] to EGFR. On the other hand, the 9F7-F11 
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Combined treatment with the anti-HER3 antibody 16D3-C1 and trastuzumab improves inhibition of
HER2 low tumor growth in nude mice
We previously demonstrated that the combination of anti-HER2 trastuzumab with anti-EGFR therapy has a synergistic anti-cancer effect in mice xenografted with HER2 low pancreatic carcinoma cells [36] .
To assess the effect on HER2 low tumor xenografts of combined treatment with trastuzumab and the anti-HER3 Ab 16D3-C1, we xenografted mice (n=8/each condition) with HER2 low epidermoid A431 or lung A549 cancer cells. Both cell lines secrete NRG [17, 37] and show no [38] or moderate [39] response to trastuzumab therapy, respectively. To highlight a potential synergistic effect, subefficient doses of 16D3-C1 and trastuzumab (10 mg/kg every 2 days for 4 weeks) were administered.
Tumor growth was significantly reduced (60% in A431 cell xenografts and 75% in A549 cell xenografts) in mice treated with both antibodies (p<0.001) at day 35 post-xenograft in comparison to mice treated with 16D3-C1 alone (25% reduction in A431 and 50% reduction in A549 xenografts) or with trastuzumab alone or vehicle (no reduction) ( Figure 5 ). These results demonstrate that the combination of an HER3-specific antibody and trastuzumab might be effective in HER2 low carcinomas that secrete NRG. [27, 29, 40] and EGFR high [25, 27] tumors. The main rationale for these combinations is that HER3 overexpression is triggered by monotreatment with EGFR-and HER2-specific Abs or small kinase inhibitors, thus allowing compensatory oncogenic signaling and cell resistance [20, 25] that could be overcome with a dual therapy, as demonstrated for the EGFR targeted therapy/anti-HER3 Ab combination in a mouse model of lung cancer [25] . Our data indicate that the anti-HER3 Ab/trastuzumab combination might represent an option for by-passing trastuzumab-induced resistance in HER2 amplified cancer, but also for targeting HER2 low cancer. Moreover, the synergistic effect of two HER3-specific Abs (e.g., NRG
antagonism for Abs 16D3-C1 or H4B-121, and NRG-independent binding for Ab 9F7-F11), or a combination of anti-HER3 Abs plus chemotherapy [27] or radiotherapy [41] , could be also envisaged to more efficiently block NRG-addicted as well as NRG-independent HER3-positive tumors.
We obtained mouse and human D1-, D3-and D4-specific Abs that can interfere or not with ligand binding. The alanine scanning analysis shows that, although charged and aromatic residues are both . As the motifs recognized by the 9F7-F11 and H4B-121 Abs overshadow the hidden D2 domain, the NRG-independent 9F7-F11 Ab might limit the NRG-induced intra-and inter-molecular flexibility of HER3, as was suggested for zalutumumab (specific for EGRF D3), whereas the NRGantagonist H4B-121 and 16D3-C1 Abs might occlude the ligand-binding domain, as was previously shown for cetuximab [35] . D1-and D3-specific Abs probably inhibit HER2/HER3 cellular heterodimerization by locking HER3 in a conformation which impairs the formation of HER3-containing dimers. Heterodimerization was not inhibited by the Abs H4B-25 and H3A-122 directed against the "hot-spot" D3/D4 junction, suggesting that this HER3 region is not directly involved, when D1 and D2 move further away from D3 and D4, after NRG activation, to open the receptor in an active conformation for dimerization. In other hand, HER3 epitope targeted by D3-specific Ab H4B-25
perfectly matched with residues identified by the A30 aptamer [42] , thus suggesting that this Ab could interfere with the side-by-side rearrangement of HER2/HER3 heterodimers leading to the formation of dimers of dimers, as proposed by Zhang et al [42] . D4-specific Ab H3A-122 will rather act by sterically locked D2/D4 interdomain tether, thus hindering NRG binding [43] .
An important feature of the anti-HER3 D1-and D3-specific Abs is their ability to inhibit NRGinduced phosphorylation of XIAP, FoxO1, GSK-3 and MDM2. HER3 carboxyl-terminal tail has 6 YXXM motifs that are phosphorylated after NRG stimulation and that directly engage the N-SH2 domain of p85 and thus activate the p110 catalytic subunit of PI3K. Recruitment and activation of PI3K leads to phosphorylation and activation of membrane-bound AKT by PDK1 and TOR complex 2. Incubation with the Abs 16D3-C1 and 9F7-F11 (anti-HER3 D1) and the Ab H4B-121 (anti-HER3 D3) blocked AKT phosphorylation at Thr 308 (induced by PDK1) and at Ser 473 (mediated by mTOR), demonstrating that both PDK1 or mTOR signaling cascades are affected. AKT is a major signaling "hub" that phosphorylates a plethora of cell substrates and as a consequence can also influence tumor growth and drug resistance [5] . and also of Insulin Receptor IGF1R [47] and the FGF receptor [21] , highlighting the layered interconnected tyrosine kinase receptor networks that could be concomitantly modulated by HER3-specific Abs. Finally, MDM2, an E3 ubiquitin-ligase that regulates p53 by promoting its ubiquitination/degradation, also favors FoxO1 ubiquitination/degradation [48] . FoxO factors and p53
perform similar functions to enable DNA repair, maintain genomic stability and coordinate cell cycle regulation and apoptosis through multiple tumor-suppressor mechanisms. XIAP possesses an E3-ubiquitin ligase activity that inhibits Caspases 3, 7 and 9 through ubiquitination/degradation [49] . phosphorylation [41] , suggesting that by-passing resistance to RTK inhibitors by modulating the p53 pathway through HER3 targeting could be an interesting way of investigation.
The binding of 9F7-F11 Ab to HER3 is NRG-independent but this Ab inhibited ligand-induced phosphorylation of HER3 and Akt, thus confirming that it rather acts by impairing dimer formation.
While a 15-min incubation with anti-HER3 Abs was sufficient to block NRG-induced phosphorylation of HER3 and AKT, antibody-induced HER3 down-regulation in NRG-stimulated BxPC3 cells occurred later, at least after 1h of incubation, and persisted throughout the experiment time course. The HER3-specific Abs might thus regulate receptor quality control [4] by accelerating HER3 endocytosis, sorting and degradation, as previously proposed by others [24] [25] [26] 28] . Upon ligand binding, HER3 .
turnover is rapid, probably chronologically-regulated by its HER heterodimerization partner (mainly HER2) and dependent on ubiquitination/deubiquitination triggered by the Nrdp1/USP8 complex [51] for degradation via the proteasomal pathway [52] .
As the membrane is a "meeting point" for extracellular therapeutic Abs and intracellular 37°C by western blotting using the appropriate Abs. HER3 down-regulation was determined after Ab incubation at 37°C or 4°C for 15 min, 1h and 2h.
